Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Parabilis Medicines (Nasdaq: PBLS) announced that its Chairman, President and CEO, Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Parabilis Medicines (Nasdaq: PBLS) announced that its Chairman, President and CEO, Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The session is scheduled for 2:35 PM ET on Wednesday, September 16, 2026, with a live audio webcast available via the Investors section of the Parabilis website.
Details
News Market Reaction – PBLS
On Sep 1, the day this news came out, PBLS closed 1.47% above the previous close. Relative volume reached 8.9x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Conference edition
- 24th annual
- Morgan Stanley Global Healthcare Conference
- Event time
- 2:35 PM ET
- September 16, 2026 fireside chat
- Event date
- September 16, 2026
- Morgan Stanley Global Healthcare Conference
Historical Context
-
New director with more than 30 years of oncology development experience
-
Earnings report included a $52.5M net loss and increased operating investment
-
Upsized IPO closed with 38,525,000 shares priced at $20.00 per share
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.
The live audio webcast will be available on the Investors section of the Parabilis website at investors.parabilismed.com.
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric ARON in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn.
Media Contact:
Jessica Freifeld
media@parabilismed.com
Investor Contact:
Tom Kotarakos
investors@parabilismed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.